Jeff Galvin BIO International Convention Digital 2021 Company Presentation
Jeff Galvin, CEO of American Gene Technologies, presents the latest news at the BIO Digital International Convention 2021. As the first patient in AGT’s Phase 1 clinical trial is infused with AGT103-T, an autologous cell therapy intended to cure HIV, the company expects to see safety data by the end of the summer, and an efficacy signal by the end of the year.
Galvin details his confidence in the potency of AGT103-T as it receives continued support from top-notch doctors and researchers, pre-clinical data validation from NIAID, and its ability to create viral vectors capable of introducing protective genes into HIV-specific CD4 T cells.
AGT aims to create the most efficient system possible for designing and developing new drug candidates. Galvin highlights AGT’s expansive platform that includes monogenic diseases and projects in immuno-oncology. Looking to the future, Galvin describes how the current Gamma Delta T cell activation technology developed by AGT can be used to treat epithelial solid tumors using a lentiviral vector called ImmunoTox.
About AGT:
American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. AGT's mission is to transform people's lives through genetic medicines that rid the body of disease.
Visit our website: https://www.americangene.com
Subscribe to our newsletter: https://bit.ly/3ughPNR
Follow the company on social media---
Twitter:
Jeff - @jeffreygalvin - / jeffreygalvin
AGT - @americangene - / americangene
LinkedIn:
Jeff - / jeff-galvin-60258
AGT - / american-gene-technologies-international-inc
Facebook/Instagram:
Facebook - / amerigene
Instagram - / americangenetechnologies